SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Solara zooms on getting CEP approval to manufacture Ibuprofen from Vishakhapatnam Facility

01 Nov 2022 Evaluate

Solara Active Pharma Sciences is currently trading at Rs. 415.00, up by 17.35 points or 4.36% from its previous closing of Rs. 397.65 on the BSE.

The scrip opened at Rs. 397.40 and has touched a high and low of Rs. 419.65 and Rs. 392.45 respectively. So far 10241 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1385.00 on 10-Nov-2021 and a 52 week low of Rs. 323.65 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 421.75 and Rs. 392.45 respectively. The current market cap of the company is Rs. 1496.90 crore.

The promoters holding in the company stood at 40.40%, while Institutions and Non-Institutions held 21.44% and 38.16% respectively.

Solara Active Pharma Sciences (Solara) has received ‘Certificate of Suitability’ (CEP) approval for its new state of the art multipurpose API manufacturing facility at Vishakhapatnam, Andhra Pradesh, for the manufacture of Ibuprofen API, from European Directorate for the Quality of Medicines (EDQM), the first international regulatory approval for this new facility.

With this key approval, Solara has CEP approval for two manufacturing facilities for Ibuprofen API, the other being its dedicated manufacturing facility located at Puducherry, India. Solara also expects series of other international regulatory approvals for its Vizag facility, including USFDA.

Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.

Solara Active Pharma Share Price

499.25 9.95 (2.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×